Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction by Do, Ron et al.
Multiple rare alleles at LDLR and APOA5 confer risk for early-
onset myocardial infarction
A full list of authors and affiliations appears at the end of the article.
Summary
Myocardial infarction (MI), a leading cause of death around the world, displays a complex pattern 
of inheritance1,2. When MI occurs early in life, the role of inheritance is substantially greater1. 
Previously, rare mutations in low-density lipoprotein (LDL) genes have been shown to contribute 
to MI risk in individual families3–8 whereas common variants at more than 45 loci have been 
associated with MI risk in the population9–15. Here, we evaluate the contribution of rare mutations 
to MI risk in the population. We sequenced the protein-coding regions of 9,793 genomes from 
patients with MI at an early age (≤50 years in males and ≤60 years in females) along with MI-free 
controls. We identified two genes where rare coding-sequence mutations were more frequent in 
cases versus controls at exome-wide significance. At low-density lipoprotein receptor (LDLR), 
carriers of rare, damaging mutations (3.1% of cases versus 1.3% of controls) were at 2.4-fold 
increased risk for MI; carriers of null alleles at LDLR were at even higher risk (13-fold difference). 
This sequence-based estimate of the proportion of early MI cases due to LDLR mutations is 
remarkably similar to an estimate made more than 40 years ago using total cholesterol16. At 
apolipoprotein A-V (APOA5), carriers of rare nonsynonymous mutations (1.4% of cases versus 
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0.6% of controls) were at 2.2-fold increased risk for MI. When compared with non-carriers, LDLR 
mutation carriers had higher plasma LDL cholesterol whereas APOA5 mutation carriers had 
higher plasma triglycerides. Recent evidence has connected MI risk with coding sequence 
mutations at two genes functionally related to APOA5, namely lipoprotein lipase15,17 and 
apolipoprotein C318,19. When combined, these observations suggest that, beyond LDL cholesterol, 
disordered metabolism of triglyceride-rich lipoproteins contributes to MI risk.
The U.S. National Heart, Lung, and Blood Institute’s Exome Sequencing Project sought to 
use exome sequencing as a tool to discover novel genes and mechanisms contributing to 
heart, lung, and blood disorders. Within this program, we designed a discovery study for the 
extreme phenotype of early-onset MI (Figure 1) since heritability is substantially greater 
when MI occurs early in life1,2. From eleven studies, we ascertained 1,088 cases with MI at 
an early age (MI in males ≤50 years old and in females ≤60 years old). As a comparison 
group, we selected 978 participants from prospective cohort studies who were of advanced 
age (males ≥60 years old or females ≥70 years old) and free of MI.
We sequenced cases and controls to high coverage by performing solution-based hybrid 
selection of exons followed by massively parallel sequencing (see Methods)20. We 
performed several quality control steps to identify and remove outlier samples and variants 
(see Methods and Supplementary Figures 1–13). Characteristics of the discovery set of 
1,027 cases and 946 controls are provided in Supplementary Tables 1–3. Across the 
autosomes, each participant had an average of 43 nonsense, 7,828 missense, 92 splice-site, 
189 indel frameshift, 366 indel non-frameshift, and 103 non-synonymous singleton variants.
We first tested whether low-frequency coding variants (defined here as a single nucleotide 
variant (SNV) or indel with minor allele frequency (MAF) between 1% and 5%) are 
associated with risk for MI in the discovery sequencing study. We observed no significant 
association of MI status with any individual variant (Supplementary Figure 14). We next 
evaluated the hypothesis that rare alleles (defined here as a SNV or indel with MAF< 1% 
frequency) collectively within a gene contribute to risk for MI (see Methods). We tested for 
an excess (or deficit) in cases versus controls of rare, non-synonymous mutations by 
aggregating together SNVs and indels with MAF < 1% (‘T1’ test) in each gene and 
comparing the counts in cases and controls21. Empirical P-values were obtained using 
permutation.
The need to aggregate rare variants poses a challenge: which variants should be aggregated? 
Ideally, one would aggregate only harmful alleles and ignore benign alleles. To enrich for 
harmful alleles, we considered three sets of variants: 1) non-synonymous only; 2) a 
“Deleterious (PolyPhen)” set consisting of non-synonymous after excluding missense alleles 
annotated as benign by PolyPhen-2 HumDiv software; and 3) “Disruptive” mutations only 
(nonsense, indel frameshift, splice-site; also referred to as “null” mutations). To account for 
multiple testing, we set exome-wide significance for this study at P=8 × 10−7, a Bonferroni 
correction for the testing of ~20,000 genes and three variant sets. When the T1 test was 
applied across these three sets of alleles in the discovery sequencing study, no gene-based 
association signal deviated from what we expected by chance (Supplementary Figure 15–
22).
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We followed up on discovery sequencing results in four ways: (1) statistical imputation; (2) 
array-based genotyping using the Illumina HumanExome Beadchip (‘Exome’ Chip); (3) 
targeted re-sequencing; and (4) additional exome sequencing (Figure 1). Imputation and 
array-based genotyping were utilized to largely evaluate low-frequency variants whereas 
targeted re-sequencing and exome sequencing were utilized to test the role of rare mutations.
With the first and second follow-up approaches - imputation (n=64,132) and array-based 
genotyping (n=15,936), we did not identify novel low-frequency variants associated with MI 
or coronary artery disease (CAD) (see Methods, Supplementary Tables 4–7 and 
Supplementary Figures 23–27). The top association results for SNVs from array-based 
genotyping are shown in Supplementary Table 8.
In the third follow-up approach, we re-sequenced several genes in additional cases and 
controls (see Methods, Supplementary Table 9). After sequencing the exons of APOA5 in 
6,721 cases and 6,711 controls, we identified 46 unique non-synonymous or splice-site 
SNVs or indel frameshifts with allele frequency <1% (Supplementary Table 10). Based on 
these variants, we observed 93 alternate allele counts in cases and 42 alternate allele counts 
in controls (P=5 × 10−7; Table 1, Figure 2 and Supplementary Table 10). This burden of 
rare mutation signal was primarily driven by mutations seen in one or two study participants 
(Figure 2 and Supplementary Table 10). Carriers of a rare APOA5 mutation had a 2.2-fold 
higher risk for MI/CAD than non-carriers (Table 1).
According to a recent report, consideration of variant sets based on multiple protein 
prediction algorithms might yield stronger association signals 22. Therefore, in exploratory 
analyses, we investigated two additional variant sets: 1) “Deleterious (Broad)” as defined by 
nonsense, splice-site, frameshift, and missense annotated as damaging by at least one of five 
protein prediction algorithms and 2) “Deleterious (Strict)” as defined by nonsense, splice-
site, frameshift, and missense annotated as damaging by all five protein prediction 
algorithms (see Methods). Carriers of a rare APOA5 “Deleterious (Strict)” mutation had an 
even higher risk for MI/CAD (3.3-fold, P=0.008).
A burden of rare mutations in APOA5 explains about 0.14% of the total variance for MI and 
roughly 0.28% of the heritability (assuming that additive genetic factors explain ~50% of 
the overall variance) (see Methods and Supplementary Table 11). When compared with 
non-carriers, carriers of rare non-synonymous APOA5 alleles had higher plasma 
triglycerides (median in carriers was 167 mg/dl versus 104 mg/dl for non-carriers, P=0.007) 
and lower high-density lipoprotein cholesterol (mean in carriers was 43 mg/dl versus 57 
mg/dl for non-carriers, P=0.007) but similar LDL cholesterol (median in carriers was 110 
mg/dl versus 108 mg/dl for non-carriers, P=0.66) (Supplementary Table 12).
In the fourth follow-up approach, we performed exome sequencing in additional early-onset 
MI/CAD cases and controls, bringing the total number of exomes analyzed to 9,793 
(Supplementary Tables 13–14). We tested for an excess (or deficit) in cases versus controls 
of rare mutations in any gene (Supplementary Figure 28 and Supplementary Tables 15–17). 
At this sample size, rare alleles collectively conferred risk for MI at exome-wide 
significance in only one gene, namely LDLR (Figure 3).
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After sequencing the exons of LDLR in 4,703 cases and 5,090 controls, we identified 156 
unique non-synonymous, splice-site SNVs and indel frameshifts with allele frequency <1% 
(Table 2 and Supplementary Table 18). Of these variants, we observed 285 alleles in cases 
(6.1% of cases) and 208 alleles in controls (4.1% of controls) (1.5-fold effect size, P=4 × 
10−6) (Table 2). When restricting analysis to the “Deleterious (PolyPhen)” set, 3.1% of cases 
and 1.3% of controls carried at least one such rare mutation, for a 2.4-fold effect size (P=1 × 
10−11). A higher effect size of 4.2-fold (P=3 × 10−11) was observed when restricting to the 
“Deleterious (Strict)” set. When restricting to disruptive alleles, 0.51% of cases and 0.04% 
of controls carried at least one such rare “disruptive” mutation, for a 13-fold effect size (P=9 
× 10−5) (Table 2 and Figure 3).
A burden of rare mutations in LDLR explains about 0.24% of the total variance for MI and 
roughly 0.48% of the heritability (see Methods and Supplementary Table 19). LDL 
cholesterol level differed based on functional class annotation with the greatest difference 
seen between carriers of “disruptive” mutations and those who did not carry any non-
synonymous mutations (279 mg/dl versus 135 mg/dl, Figure 3 and Supplementary Table 
20). Approximately 49% of the LDLR alleles discovered in this study (77 of 156) have been 
previously associated with familial hypercholesterolemia in LDLR FH databases23 
(Supplementary Table 21).
Using these rare variant signals as a guide, we estimated sample sizes that will be required to 
make similar discoveries. A very large number of samples – at least 10,000 exomes – are 
required to achieve 80% statistical power at an exome-wide level of statistical significance 
(Supplementary Figure 29–31).
Here, we show that a burden of multiple rare alleles in two genes - LDLR and APOA5 - 
contributes to risk for MI. These results suggest several conclusions regarding the inherited 
basis for MI and rare variant association studies. First, after a DNA sequence-based search 
across nearly all protein-coding genes in >9,700 early-onset MI cases and controls, LDLR is 
the strongest association signal, where mutations in the gene account for about 3% of cases. 
In 1973, Goldstein and colleagues studied survivors of early MI and noted two common 
lipid abnormalities - hypercholesterolemia and hypertriglyceridemia16. Based on a total 
cholesterol value exceeding ~285 mg/dl, it was estimated that 4.1% of cases with MI prior 
the age of 60 had familial hypercholesterolemia; this original estimate is similar to ours 
based on direct sequencing. In contrast, the prevalence of harmful LDLR mutations in the 
general population is several orders of magnitude higher than the original estimate (~0.5 – 
1.3% in the present study versus 0.1 – 0.2% by Goldstein). Second, the rare variant 
association signal presented here establishes APOA5 as a bona fide MI gene. Initially 
discovered through comparative genomics analysis of a region harboring several lipid 
regulators (i.e., APOA1 and APOC3), the APOA5 locus harbors common variants associated 
with plasma triglycerides24. Candidate gene studies have associated a common variant at 
this locus also with MI risk (−1131T>C, APOA5 promoter region, rs662799, MAF of 
8%)25,26. However, due to extensive linkage disequilibrium in this region, it had been 
previously uncertain which gene is responsible for the association with MI. The 
identification of multiple coding sequence variants within APOA5 clarifies that this gene 
contributes to MI risk in the population. Third, these data point to a route to MI beyond LDL 
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cholesterol, namely triglyceride-rich lipoproteins27 and the lipoprotein lipase pathway. 
Genetic variation at two other proteins related to APOA5 function, apolipoprotein C-
III18,19,28 and lipoprotein lipase15, have been associated with triglycerides and MI risk. 
Finally, the present study makes clear that rare variant discovery for complex disease will 
require the sequencing of thousands of cases and careful statistical analysis. Two reasons for 
the large sample size requirement are an inability to readily distinguish harmful from benign 
alleles and the extreme rarity of harmful alleles.
Methods
General Overview of the Exome Sequencing Project (ESP)
Details of the study design of the National Heart, Lung and Blood Institute’s GO Exome 
Sequencing Project (NHLBI ESP) have been published previously 29. Briefly, the goal of 
the NHLBI ESP was to discover rare coding variation in genes contributing to heart, lung 
and blood disorders using next generation sequencing of the protein coding regions of the 
genome (“exome sequencing”). The study includes five primary groups including: Seattle 
GO – University of Washington, Seattle, WA; Broad GO – Broad Institute, Cambridge, MA; 
WHISP – Ohio State University Medical Center, Columbus, OH; Lung GO – University of 
Washington, Seattle, WA; Heart GO – University of Virginia Health System, 
Charlottesville, VA and two collaborating groups, WashU GO – Washington University, St. 
Louis and CHARGE-S GO – University of Texas Health Sciences Center, Houston, TX.
We included samples from several studies: Women’s Health Initiative (WHI); Framingham 
Heart Study (FHS); Jackson Heart Study (JHS); Multi-Ethnic Study of Atherosclerosis 
(MESA); Atherosclerosis Risk in Communities (ARIC); Coronary Artery Risk Development 
in Adults (CARDIA); Cardiovascular Health Study (CHS); Lung Health Study (LHS); 
COPD Genetic Epidemiology (COPD Gene); Severe Asthma Research Project (SARP); 
Pulmonary Arterial Hypertension (PAH); Acute Lung Injury (ALI); Cystic Fibrosis (CF); 
Cleveland Clinic Genebank (CCGB); Massachusetts General Hospital Premature Coronary 
Artery Disease Study (MGH PCAD); Heart Attack Risk in Puget Sound (HARPS); 
Translational Research Underlying Disparities in Myocardial Infarction Patients’ Health 
Status (TRIUMPH) and the PennCath study.
General Overview of the ESP Early-Onset Myocardial Infarction Study
Within the NHLBI ESP, we designed an exome sequencing experiment specifically to study 
early-onset myocardial infarction (EOMI). We selected EOMI cases and controls from 
eleven studies, including: ARIC, MESA, CCGB, FHS, HARPS, MGH-PCAD, PennCath, 
TRIUMPH, WHI, CHS, and JHS (Supplementary Tables 1–3). Samples were selected based 
on the extreme tails of the phenotypic distribution, in order to enrich for a genetic 
contribution to disease. EOMI cases were defined as individuals who had a MI at an age of 
≤50 for men and ≤60 for women. Controls were selected as individuals with no history of 
MI at baseline or during follow-up to at least age 60 for men and 70 for women. The study 
samples, along with case and control definitions, are briefly described below and shown in 
Supplementary Tables 1–3.
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Study and Phenotype Descriptions for ESP EOMI
a. The HeartGO Consortium—HeartGO is a multiethnic consortium consisting of six 
NHLBI population-based cohorts of men and women: ARIC, CHS, FHS, CARDIA, JHS, 
and MESA. The age range of participants in these six cohorts spans the spectrum from early 
adulthood to old age, providing a broad age representation. Each participating cohort in 
HeartGO has completed ascertainment of multiple phenotypes, including all of the major 
cardiovascular risk factors (blood pressure, lipids, diabetes status), biomarkers including 
measures of blood cell counts, subclinical disease imaging, and cardiovascular and lung 
outcomes including MI and stroke. Participants in all six cohorts provided written informed 
consent. The NIH database of Genotypes and Phenotypes (dbGaP) site contains further 
details regarding the phenotypes accessible for each individual HeartGO cohort.
b. Cleveland Clinic GeneBank (CCGB)—The CCGB study is a single-center 
prospective cohort-based study that enrolled patients undergoing elective diagnostic 
coronary angiography between 2001 and 2006. Coronary artery disease (CAD) was defined 
as adjudicated diagnoses of stable or unstable angina, MI (adjudicated definition based on 
defined electrocardiographic changes or elevated cardiac enzymes), angiographic evidence 
of ≥ 50% stenosis of one or more major epicardial vessel, and/or a history of known CAD 
(documented MI, CAD, or history of revascularization).
c. Heart Attack Risk in Puget Sound (HARPS)—The HARPS study is a population-
based case-control study that enrolled cases with incident MI presenting to a network of 
hospitals in the metropolitan Seattle-Puget Sound region of Washington State between 1998 
and 2002.
d. Massachusetts General Hospital - Premature Coronary Artery Disease 
(MGH-PCAD) Study—The MGH-PCAD study is a hospital-based case-control study that 
enrolled cases hospitalized with early MI at MGH between 1999 and 2004.
e. PennCath—The PennCath study is a catheterization-lab based cohort study from the 
University of Pennsylvania Medical Center and enrolled subjects at the time of cardiac 
catheterization and coronary angiography between 1998 and 2003. Persons undergoing 
cardiac catheterization at either the Hospital of the University of Pennsylvania or Penn 
Presbyterian Medical Center consented for the PennCath study to identify genetic and 
biochemical factors related to coronary disease.
f. Translational Research Investigating Underlying Disparities in Acute 
Myocardial Infarction Patients’ Health Status (TRIUMPH)—The TRIUMPH study 
is a large, prospective, observational cohort study of consecutive patients with acute MI 
presenting to 24 US hospitals from April 2005 to December 2008. MI was diagnosed using 
contemporary definitions 30 and all patients had an elevated troponin blood test.
g. Women’s Health Initiative—The Women’s Health Initiative (WHI) is a major 
research program that has been ongoing for over 20 years to address the most common 
causes of death, disability and poor quality of life in postmenopausal women -- 
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cardiovascular disease, cancer, and osteoporosis. Cases were defined based on the 
occurrence of MI, coronary revascularization, hospitalized angina or death due to coronary 
disease.
Studies Involved in Follow-up Statistical Imputation, Array-based Genotyping, Targeted 
Resequencing and Additional Exome Sequencing
a. Statistical Imputation—We performed imputation of single nucleotide variants 
(SNVs) discovered in the exomes of 786 samples. We imputed exomic SNVs into 64,132 
independent samples in 16 studies to test for association of coding SNVs with MI or CAD. 
The studies are described in Supplementary Table 5.
b. Array-based Genotyping—We performed follow-up genotyping using the Illumina 
HumanExome Beadchip (“Exome Chip”) array in 15,936 independent samples from seven 
studies. The studies are described in Supplementary Table 7.
c. Targeted Sequencing—We performed targeted sequencing of the APOA5 gene in an 
additional 11,414 individuals from five cohorts. The studies are described in Supplementary 
Table 9.
d. Exome Sequencing-based Follow-up—We leveraged additional exomes from the 
ESP study and performed exome sequencing in additional individuals from three cohorts. 
The studies are described in Supplementary Table 13.
Detailed methods for the processing and analysis of samples for the various stages of the 
project are described below. We describe methods for the different stages of the project, 
including discovery exome sequencing and follow-up imputation, array-based genotyping, 
targeted re-sequencing and additional exome sequencing.
Laboratory Methods for Discovery Exome Sequencing in the ESP EOMI Project
a. Exome Sequencing—Exome sequencing was performed at the Broad Institute. 
Sequencing and exome capture methods have been previously described 29. A brief 
description of the methods is provided below.
b. Receipt/Quality Control of Sample DNA—Samples were shipped to the Biological 
Samples Platform laboratory at the Broad Institute of MIT and Harvard. DNA concentration 
was determined by the Picogreen assay (Invitrogen) before storage in 2D-barcoded 0.75 mL 
Matrix tubes at −20°C in the SmaRTStore™ (RTS, Manchester, UK) automated sample 
handling system. We performed initial quality control (QC) on all samples involving sample 
quantification (PicoGreen), confirmation of high-molecular weight DNA and fingerprint 
genotyping and gender determination (Illumina iSelect). Samples were excluded if the total 
mass, concentration, integrity of DNA or quality of preliminary genotyping data was too 
low.
c. Library Construction and In-Solution Hybrid Selection—Starting with 3μg of 
genomic DNA, library construction and in-solution hybrid selection were performed as 
described previously 31. A subset of samples, however, was prepared using the Fisher et al. 
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protocol with some slight modifications. Initial genomic DNA input into shearing was 
reduced from 3μg to 100ng in 50μL of solution. In addition, for adapter ligation, Illumina 
paired end adapters were replaced with palindromic forked adapters with unique 8 base 
index sequences embedded within the adapter.
d. Preparation of Libraries for Cluster Amplification and Sequencing—After in-
solution hybrid selection, libraries were quantified using qPCR (KAPA Biosystems) with 
probes specific to the ends of the adapters. This assay was automated using Agilent’s Bravo 
liquid handling platform. Based on qPCR quantification, libraries were normalized to 2nM 
and then denatured using 0.1 N NaOH using Perkin-Elmer’s MultiProbe liquid handling 
platform. A subset of the samples prepared using forked, indexed adapters was quantified 
using qPCR, normalized to 2nM using Perkin-Elmer’s Mini-Janus liquid handling platform, 
and pooled by equal volume using the Agilent Bravo. Pools were then denatured using 0.1 N 
NaOH. Denatured samples were diluted into strip tubes using the Perkin-Elmer MultiProbe.
e. Cluster Amplification and Sequencing—Cluster amplification of denatured 
templates was performed according to the manufacturer’s protocol (Illumina) using either 
Genome Analyzer v3, Genome Analyzer v4, or HiSeq 2,000 v2 cluster chemistry and 
flowcells. After cluster amplification, SYBR Green dye was added to all flowcell lanes, and 
a portion of each lane visualized using a light microscope, in order to confirm target cluster 
density. Flowcells were sequenced either on Genome Analyzer II using v3 and v4 
Sequencing-by-Synthesis Kits, then analyzed using RTA v1.7.48, or on HiSeq 2,000 using 
HiSeq 2,000 v2 Sequencing-by-Synthesis Kits, then analyzed using RTA v1.10.15. All 
samples were run on 76 cycle, paired end runs. For samples prepared using forked, indexed 
adapters, Illumina’s Multiplexing Sequencing Primer Kit was also used.
f. Read Mapping and Variant analysis—Samples were processed from real-time base-
calls (RTA 1.7 software [Bustard], converted to qseq.txt files, and aligned to a human 
reference (hg19) using Burrows-Wheeler Aligner (BWA, see URL 32). Aligned reads 
duplicating the start position of another read were flagged as duplicates and not analyzed 
(“duplicate removal”). Data was processed using the Genome Analysis ToolKit (GATK 
v1.1.3 33). Reads were locally realigned (GATK IndelRealigner) and their base qualities 
were recalibrated (GATK TableRecalibration). Variant detection and genotyping were 
performed on both exomes and flanking 50 base pairs of intronic sequence using the 
UnifiedGenotyper (UG) tool from the GATK. Variant data for each sample was formatted 
(variant call format (VCF)) as “raw” calls for all samples. SNVs and indel sites were flagged 
using the Variant Filtration walker (GATK) to mark sites of low quality that were likely 
false positives. SNVs were marked as potential errors if they exhibited strong strand bias 
(SB >= 0.10), low average quality (quality per depth of coverage (QD) <5.0), or fell in a 
homopolymer run (HRun > 4). Indels were marked as potential errors for low quality 
(quality score (QUAL) < 30.0), low average quality (QD < 2.0), or if the site exhibited 
strong strand bias (SB > -1.0). Samples were considered complete when exome targeted read 
coverage was ≥20X over ≥80% of the exome target.
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g. Data Analysis QC—Fingerprint concordance between sequence data and fingerprint 
genotypes was evaluated. Variant calls were evaluated on both bulk and per-sample 
properties: novel and known variant counts, transition-transversion (TS-TV) ratio, 
heterozygous-homozygous non-reference ratio, and deletion/insertion ratio. Both bulk and 
sample metrics were compared to historical values for exome sequencing projects at the 
Broad Institute. No significant deviation of the ESP variants or ESP samples from historical 
values was noted.
Data Processing, Quality Control and Association Analysis of Discovery Exome 
Sequencing
a. Variant Calling—Variants (SNVs and indels) were identified and genotyped from 
recalibrated BAM files 34 using the multi-sample processing mode of the Unified Genotyper 
tool from the GATK. Variants were first identified and genotyped in random batches of 100 
samples. The batches were then merged into a single VCF file using the GATK 
CombineVariants tool.
b. Variant Annotation—Variants (SNVs and indels) were annotated using the 
GRCh37.64 database using the SNP effect predictor tool (SnpEff, see URL) 35 and the 
GATK VariantAnnotator. The primary SnpEff genomic effects that were annotated include: 
splice-site acceptor, splice-site donor, indel frameshift, indel non-frameshift, nonsense, non-
synonymous and synonymous variants. For variants that have different annotations due to 
multiple transcripts of the gene, the highest impact effect for each variant was taken.
c. Sample Level Quality Control—We performed several quality control steps to 
identify and remove outlier samples (Supplementary Figures 1–8). First, we required that 
each sample had a minimum of 20-fold coverage for at least 80% of the targeted bases. 
Second, we compared self-reported ancestry with that inferred from the sequence data and 
removed discordant samples. Third, we removed samples with high degree of heterozygosity 
and low number of singleton counts as this pattern suggests DNA contamination across 
samples. Fourth, we removed samples with an extremely high number of variants or 
singletons as this can suggest low quality DNA. Finally, we removed samples exhibiting a 
mismatch between the reported gender and that inferred from sequence data. Of 2,066 cases 
and controls sequenced across the exome, we removed 93 samples due to these exclusion 
criteria.
d. Variant Level Quality Control—QC measures were also performed to remove low 
quality variants. We assessed population genetics metrics including the TS-TV ratio, the 
ratio of the number of heterozygous changes to the number of homozygous non-reference 
changes, and the number of non-synonymous to the number of synonymous changes. This 
analysis can help filter false positive calls since we expect the true TS-TV to be around ~3.2 
in European populations 33, while a set of random SNVs (or false positive variants) should 
give a random expectation of 0.5. Variants with low depth of coverage (DP) and high 
percent missingness generally had low TS-TV and heterozygous-homozygous non-reference 
ratios. Variants were removed if there was DP < 8 average per sample and > 2% 
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missingness (Supplementary Figures 9–12). Distribution of allele frequencies of the SNVs is 
shown in Supplementary Figure 13.
e. Common Variant Association Analysis—We performed single variant association 
analysis in our exome sequencing dataset. For SNVs with minor allele frequency (MAF) 
greater than 5%, we ran logistic regression, after adjusting for 10 principal components 
while for SNVs with MAF less than 5%, we ran Fisher’s Exact test. We performed 
association analysis in European Americans and African Americans separately and then 
performed sample size weighted meta-analysis using METAL 36. The association results are 
shown in Supplementary Figure 14.
f. Rare Variant Association Analysis—To test whether rare mutations contribute to 
MI, we performed burden of rare variant analysis on the ~2,000 ESP EOMI exome samples. 
We performed a variant of the Combined Multivariate Collapsing test 21, that groups the 
count of alleles of SNVs in cases and controls. Phenotype labels were permuted 100,000 
times to assign a statistical significance. We accounted for ethnicity by permuting phenotype 
labels within each ethnicity. Association analysis was performed using PLINK/SEQ (see 
URL).
We collapsed variants based on computational predictions from PolyPhen-2 HumDiv 37. 
Minor allele frequencies were calculated from all available samples sequenced in each study 
in order to obtain the most accurate MAF estimates. Therefore, calculation of MAF for ESP 
EOMI 1 and 2 was performed on a larger set of exome samples that were sequenced at the 
Broad Institute as part of ESP (n=970 exomes for ESP EOMI 1 and n=3014 for ESP EOMI 
2). For our burden of rare variant association analysis, we use a MAF threshold of 1% (T1). 
Furthermore, we use three different types of variant groupings when collapsing by gene. 
These variant groups are: 1) non-synonymous only; 2) a deleterious set consisting of non-
synonymous after excluding missense alleles annotated as benign by PolyPhen-2 HumDiv 
software; and 3) disruptive (nonsense, indel frameshift, splice-site) mutations only. We also 
performed the T1 test after collapsing all non-synonymous mutations by KEGG pathways 
(Supplementary Figure 21 and 22).
Methods for Follow-up Statistical Imputation
a. Construction of Reference Panels and Targeted Imputation Panels—Exome 
imputations were performed using two reference panels and 16 targeted imputation panels. 
A total of 697 ESP samples (436 African Americans and 261 European Americans) were 
used for the first reference panel while 89 samples from the 1000 Genomes Project 38 were 
drawn for the second reference panel. For the ESP reference panel, all samples from ARIC 
(n=212), JHS (n=119), MIGen (n=151) and WHI studies (n=41) were genotyped using 
commercially available Affymetrix 6.0 arrays. Samples from the FHS (n=174) were 
genotyped using the Affymetrix 5.0 array. The second reference panel was comprised of 
samples from the 1000 Genomes Project that had genotype data for both low coverage 
sequencing and high coverage exome sequencing data 38. A total of 89 samples were 
selected from 6 diverse populations (23 African Ancestry in Southwest US (ASW), 9 Utah 
residents with Northern and Western European ancestry (CEU), 12 Colombian in Medellin, 
Do et al. Page 10













Colombia (CLM), 25 Mexican Ancestry in Los Angeles, CA (MXL), 17 Toscani in Italia 
(TSI) and 3 Yoruba in Ibadan, Nigeria (YRI) samples). Low coverage whole genome 
sequencing, high coverage exome sequencing and targeted exome capture were performed 
based on standard protocols at the Broad Institute. Details of the sequencing methods and 
samples have been described previously 38. Imputation was performed into 16 independent 
study samples with genome-wide genotype data. Study samples were genotyped using 
commercially available Affymetrix or Illumina genotyping arrays. Further details are 
described in Supplementary Table 5.
Reference panels were created by merging genotypes from SNVs that span the entire 
genome (hence, providing a haplotype “scaffold”), with genotypes from SNVs from ESP 
exome sequencing data. The first reference panel was generated using genotypes from both 
genome-wide SNV arrays obtained from dbGAP and exome sequencing data. The second 
reference panel was generated using genotype data for both low coverage sequencing and 
high coverage exome sequencing data. Both the reference panel and targeted genome-wide 
panel were phased using the “best guess haplotypes” option in IMPUTE2 39. Haplotype 
phasing were performed in 5 megabase chunks as recommended by the software tutorial 39.
b. Data Processing, Quality Control and Association Analysis—Imputation of the 
exome was performed using IMPUTE2. We imputed approximately 400,000 coding SNVs 
from the reference panels into 28,068 cases and 36,064 controls from 16 different study 
samples with genome-wide data. Descriptions for the study samples have been reported 
elsewhere (Supplementary Table 5 for references). We filtered SNVs with MAF < 1% and 
imputation quality (INFO) < 0.5 from further analysis. The distribution of imputation 
qualities of the SNVs is shown in Supplementary Figure 23–24. Association testing for 
CAD/MI was performed using the score method and assuming an additive model in 
SNPTEST (see URL) 40. Age, sex and the first two principal components were used as 
covariates when appropriate. We did not observe any indication of excess inflation of test 
statistics in any of the study samples (Supplementary Table 22). Meta-analysis of study-
specific P-values for imputed SNVs was performed using the Z-score method weighted by 
sample size in METAL (see URL). Beta and standard errors were estimated based on an 
inverse-weighted meta-analysis. The distribution of association results for the imputation 
results is shown in Supplementary Figure 25 and top association results in Supplementary 
Table 6.
Methods for Follow-up Array-Based Genotyping
a. Laboratory Methods—DNA samples were sent to the Broad Institute Genetic 
Analysis Platform for genotyping and were placed on 96-well plates for processing using the 
Illumina HumanExome v1.0 SNP array. Genotypes were assigned using GenomeStudio 
v2010.3 using the calling algorithm/genotyping module version 1.8.4 along with the custom 
cluster file StanCtrExChp_CEPH.egt. Only samples passing an overall call rate of 98% 
criteria and standard identity check were released from the Genetic Analysis Platform.
b. Data Processing, Quality Control and Association Analysis—To identify 
single low frequency SNVs associated with MI or CAD, we performed array-based 
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genotyping using the Illumina Human Exome Beadchip. We genotyped 83,680 sites 
identified from exome sequencing in 1,027 early-onset MI cases and 946 controls. The 
samples for genotyping were drawn from the cohorts listed in Supplementary Table 7 and 
have been previously described. The functional effect of each variant was predicted using 
the SeattleSeq Annotation server (see URL). For variants having more than one functional 
class, the most deleterious class was retained.
Several quality control processes were employed to ensure high quality genotypes and 
samples were used in the association analysis. Samples were excluded for the following 
criteria: greater than 5% missing genotypes; discordance between inferred gender based on 
genotype and self-reported gender; inbreeding coefficient less than −0.2 or greater than 0.2; 
duplicated samples; or proportion of genotypes identical by descent > 0.2. In addition, 
principal components were calculated using Eigenstrat 4.2 41 and samples were removed if 
they were found to be statistical population outliers. Variants were removed for the 
following criteria: MAF = 0%; significant difference between missingness in cases 
compared with controls; extreme deviation from Hardy-Weinberg equilibrium (P < 1×10−6); 
or significant association with genotyping plate assignment. All quality control filtering 
were performed using PLINK (see URL) 42 and R (see URL, The R Project for Statistical 
Computing, Vienna, Austria).
Association testing for CAD/MI was performed within each study separately using logistic 
regression with ten principal components of ancestry as covariates. An inverse standard-
error weighted meta-analysis was performed to combine results across studies. The 
association testing was performed using PLINK 42 and the meta-analysis was performed 
using METAL. There was no indication of an inflation of test statistics across studies 
(Supplementary Table 23). The stability of logistic regression was assessed by examining 
the standard error of the beta estimate as a function of minor allele frequency (see 
Supplementary Figure 32). As shown, logistic regression is unstable for a MAF < 0.05%. 
Fisher’s Exact test was used for variants with MAF < 0.05%. The top association results are 
shown in Supplementary Table 8.
Methods for Follow-up Resequencing
a. Selection of Genes—We first selected six associated genes (based on biologic and/or 
statistical evidence with T1 P < 0.005; APOA5, CHRM5, SMG7, LYRM1, APOC3, NBEAL1) 
for replication sequencing in the ATVB study (Supplementary Table 24) where all cases had 
suffered an MI prior to age of 46. We also pursued the same six genes in the Ottawa Heart 
Study with 552 cases and 586 controls (Supplementary Table 25). One of the genes 
(APOA5) continued to show significant results and was sequenced in three additional studies 
(Table 1 and Supplementary Table 26). In total, we performed follow-up sequencing of 
APOA5 in six study samples, including the Verona Heart Study (VHS), Ottawa Heart Study 
(OHS), additional exomes from Atherosclerosis, Thrombosis, and Vascular Biology Italian 
Study Group (ATVB), additional exomes from the ESP EOMI study (ESP EOMI 2), 
Precocious Coronary Artery Disease study (PROCARDIS), and the Copenhagen City Heart 
Study and Copenhagen Ischemic Heart Disease Study (CCHS/CIHDS).
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b. Laboratory Methods—For the VHS study, genomic DNA was extracted from white 
blood cells using the salting-out method. The protein-coding regions corresponding to the 
RefGene transcripts NM_052968 for APOA5 and NM_012125 for CHRM5 were sequenced 
using in-house designed primers (available on request) and the BigDye Terminator Cycle 
Sequencing Kit v1.1 on an ABI-3130XL Genetic Analyzer (Applied Biosystems, Foster 
City, CA). SNVs were called using the Variant Reporter software v1.1 (Applied 
Biosystems).
For the OHS study, PCR primers were designed, tested and optimized to target the exons 
and flanking non-coding sequences for each gene. Sequencing reactions were performed 
using big dye terminator chemistry and chromatograms obtained with an Applied 
Biosystems ABI 3730XL capillary sequencer. Chromatograms were base-called by using 
Phred, assembled into contigs by using Phrap, and scanned for SNVs with PolyPhred 43 to 
identify polymorphic sites. Each read was trimmed to remove low-quality sequence (Phred 
score <25), resulting in analyzed reads with an average Phred quality of 40. After assembly 
and variant calling, each polymorphic sites were reviewed by a data analyst using Consed 44 
to ensure the quality and accuracy of the variant calls. This process generates sequence-
based SNV genotypes with accuracy > 99.9%.
For the PROCARDIS study, a single long range PCR product (LRPCR) was amplified to 
provide coverage of the APOA5 exonic, intronic and flanking sequences (human reference 
sequence NCBI build 37 chromosome 11:116,659,905–116,664,331). The LRPCR products 
were tagged with unique sequence (barcode) adaptors, and processed into 56 short 
amplicons (Reflex ™ reactions - www.populationgenetics.com) and pooled for multiplex 
next-generation sequencing (NGS). NGS was performed on a MiSeq™ personal sequencer 
to >20x coverage across 95% of the APOA5 target region on 1,385 MI cases and 1,499 
controls. Paired-end reads were mapped to NCBI build 37 using the BWA and SMALT 
aligners; variants were identified by the GATK unified genotyper (v1.6.13) and annotated 
using SnpEff v2.0.5 and the GRCh37.64 database.
For the CCHS/CIHDS study, lightscanner screening and resequencing were performed. 
Genomic DNA was isolated from frozen whole blood (QiaAmp4 DNA blood mini kit; 
QIAGEN GmbH, Hilden, Germany). Six PCR fragments were amplified covering the three 
coding exons and adjacent splice-sites (approximately 20 base-pairs upstream and 
downstream each exon) of APOA5. Mutational analysis of the PCR products was performed 
by high resolution melting curve (HRM) analysis using the Lightscanner™ system (Idaho 
Technology Inc. Salt Lake City, Utah). PCR fragments showing heteroduplex formation by 
HRM analysis were subsequently sequenced on an ABI 3730 DNA analyzer (Applied 
Biosystems Inc., Foster City, CA).
c. Data Processing, Quality Control and Association Analysis—After 
sequencing, variants were annotated using SnpEff or Annovar 45. For each study, only non-
synonymous SNVs with MAF < 1% were analyzed. Rare variant burden testing was 
performed using the T1 test. Meta-analysis was performed to combine evidence across study 
specific P-values using the sample size weighted Z-score method, implemented in METAL. 
Association results and a listing of APOA5 mutations discovered from sequencing are 
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described in Table 1 and Supplementary Table 10. P-values for association between APOA5 
mutation carrier status and lipid traits were performed using the Mann-Whitney ranksum 
test. Results are shown in Supplementary Table 12.
Methods for Follow-up Exome Sequencing
a. Laboratory Methods—We performed follow-up exome sequencing in additional 
samples from three other studies. Sequencing was performed at the Broad Institute, using the 
same protocols described above for the NHLBI ESP Project.
b. Data Processing, Quality Control and Association Analysis—Variant calling 
and annotations were performed as described above for the NHBLI ESP EOMI. Quality 
control of samples was performed using the following steps. To detect mismatched samples, 
we calculated discordance rates between genotypes from exome sequencing with genotypes 
from array-based genotyping. We removed samples with discordance rate > 0.02. We tested 
for sample contamination using verifyBamID 46, which examines the proportion of non-
reference bases at reference sites. We removed samples with FREEMIX or CHIPMIX scores 
> 0.2. Furthermore, we removed outlier samples with too many or too few SNVs (>700 or 
<5 singletons, >400 or <5 doubletons), and those with too high or low TS-TV (>4 or <3) and 
heterozygosity (heterozygote to homozygote ratio >6 or <2). Finally, we removed samples 
with high missingness (>0.1). In total, 202 samples were removed. For quality control of 
variants, we removed SNPs and indels that had low recalibration scores after running GATK 
VariantRecalibrator. We also removed SNVs with low coverage (DP < 140000 and quality 
over depth (QD) < 2) and high missingness (frequency of missing genotypes > 0.02). For 
quality control of indels, we removed indels that had excessive strand bias (Fisher Strand > 
200), high proportion of alternate alleles seen near the ends of reads (ReadPosRankSum < 
−20), deviation from Hardy-Weinberg equilibrium (InbreedingCoeff < −0.8) and low 
coverage (QD < 3). Rare variant association analysis was performed using EPACTS (see 
URL). We performed burden of rare variant analysis using the Efficient Mixed-Model 
Association eXpedited (EMMAX) Combined Multivariate and Collapsing (CMC) test 47. 
This approach uses a kinship matrix to take into account population structure. We restricted 
analyses to SNVs and indels with minor allele frequency < 0.01. Furthermore, we restricted 
analyses to three different sets of variants: 1) non-synonymous only; 2) a deleterious set 
consisting of non-synonymous after excluding missense alleles annotated as benign by 
PolyPhen-2 HumDiv software; and 3) disruptive (nonsense, indel frameshift, splice-site) 
mutations only.
Estimation of Heritability Explained by a Burden of Rare Mutations in the APOA5 and 
LDLR Genes
We calculated the heritability explained by a burden of rare mutations in the APOA5 and 
LDLR genes using the following assumptions. We assumed that the alleles come from a 
mixture of two distributions: harmless alleles, with no effect on the trait, and null alleles, 
which destroy the function of the gene, and have an (constant) effect on the trait. We 
assumed different values for the fraction of null alleles, α (our current expectation for most 
genes for α is around 1/3–1/2 for missense alleles. Here, we clump missense alleles together 
with nonsense alleles, which should slightly increase α). The variance explained is sensitive 
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to this parameter. We assumed a liability-threshold model for disease, with an underlying 
(un-observed) continuous trait representing risk for MI, and MI occurring if risk is above a 
certain threshold. We assume all null alleles have effect β (in units of standard deviations) 
on the liability scale. We assumed different values for the prevalence (denoted κ) for early 
MI (3% to 5%). Results are somewhat sensitive to prevalence; higher prevalence will 
slightly increase heritability estimates. Given the prevalence, the number of carriers in cases 
and controls gives us the allele frequency in the population (which is very close to the allele 
frequency in controls).
We fitted the effect size (β on liability scale) and alleles for different values of α and κ. 
Results for APOA5 are shown in Supplementary Table 11 and results for LDLR are shown in 
Supplementary Table 19. For APOA5, β is moderate (up to roughly one standard deviation), 
with variance explained between 0.08% and 0.17% of the total phenotypic variance (on the 
liability scale). If we assume the heritability of MI is 50%, a burden of rare mutations in the 
APOA5 gene may explain 0.16–0.34% of the heritability. For LDLR, for all values, variance 
explained is between 0.13% and 0.32% of the total phenotypic variance (on the liability 
scale) and 0.26–0.64% of the heritability.
Sample Size Extrapolations and Power Calculations for Burden of Rare Variants
We evaluated the sample size that is needed to reach genome-wide significance levels 
(P=2.5 × 10−6) for the T1 test. Our calculations relied on the following assumptions. We 
assumed that all allelic variants with population frequency less than 1% are causal and have 
identical effect sizes. We also assumed that all alleles with frequency greater than 1% were 
benign.
Our calculations differentiate between the allele frequency of a SNV in our exome samples 
with its true allele frequency in a population. The T1 test compares the number of carriers of 
an allele for a SNV with sample (rather than population) allele frequency less than 1% 
among cases and controls. We considered three factors when extrapolating to larger sample 
sizes. First, we assumed our sample is comprised of 50% cases and 50% controls. Since the 
prevalence of EOMI is estimated to be 5%, the sample frequency of causal alleles is likely to 
be higher than the population frequency. Second, some alleles with population frequency 
below 1% may, by chance, have sampling frequency greater than 1% and therefore be 
excluded from the test. Third, the true allele frequency of the SNVs in the population is 
unknown. In contrast to earlier work that relied on population genetics modeling 48, we 
provide an update on the power needed to detect rare variant signal after considering the 
three factors above. We calculated liberal and conservative estimates for our sample size 
extrapolations and power calculations. The conservative estimate was based on the estimate 
of the total population frequency of all causal alleles (below 1%) that would be unlikely to 
be excluded from the T1 test due to the sampling frequencies exceeding 1%. Because allele 
frequency distribution is dominated by rare alleles, for an allele with population frequency x̂, 
expected population allele frequency is smaller than x.
(1)
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Therefore, the expected total population frequency of all alleles below frequency x is smaller 
than the total sampling frequency of alleles below sampling frequency x̂. However, setting x̂ 
at 1% would result in a liberal rather than conservative estimate because alleles with 
population frequency below 1% may be excluded from the T1 test as having sampling 
frequency above 1%. This occurs due to oversampling cases (our sample has 50% of cases 
at disease prevalence of 5%) and sampling variance. For example, assuming only one causal 
allele per gene, the power of the T1 test is maximal for the population allele frequency close 
to 0.5% for a sample of 1,000 cases and 1,000 controls. For a sample of 10,000 individuals, 
the chance that a risk allele with population frequency of 0.5% would be excluded from the 
T1 test is below 10−3, making this threshold even more conservative. Therefore, for a 
conservative estimate, we have assumed that the total population frequency of all causal 
alleles per gene would equal the total sampling frequency of alleles below 0.5% in the ESP 
sample. Our liberal estimate assumed that all causal alleles will be included in the T1 test. 
We assumed that the total population frequency of all causal alleles per gene would equal 
the total sampling frequency of alleles below 1% in the ESP sample.
Once we extrapolated the number of mutation carriers to 20,000 samples, we then performed 
power calculations to see how many samples would be needed to reach a genome-wide 
significance level for the T1 test (P=2.5 × 10−6 after correcting for 18,500 genes). Power 
calculations were performed by first sampling a genotype at random from the pool of 20,000 
simulated samples. Based on the T1 carrier status of the drawn sample, we simulated the 
phenotype based on a calculated probability. The phenotype was simulated based on a 
prevalence rate of 5% for disease, carrier status of the random sample and assumed relative 
risk of 2.0 of the mutation. For T1 carriers, the probability of being a case was calculated as 
relative risk (RR) of T1 carrier multiplied by prevalence rate of disease (RR * prevalence 
rate). For non-carriers, the probability of being a case was simply the prevalence rate. The 
case-control ratio was 1:1. We performed sample size extrapolations for genes with varying 
number of T1 mutations (25th percentile, median and 75th percentile of carriers with a T1 
mutation for all genes discovered in the exome, Supplementary Figures 29–31).
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Figure 1. Overall design for the Early-Onset Myocardial Infarction Study within the U.S. 
National Heart, Lung, and Blood Institute’s Exome Sequencing Project
Whole exome sequencing was performed in 1,973 individuals from the phenotypic 
extremes. To test the hypothesis that low-frequency variants confer risk for myocardial 
infarction (MI), we performed follow-up statistical imputation and array-based genotyping 
of single nucleotide variants. To test the hypothesis that a burden of rare mutations in a gene 
confers risk for MI, we performed targeted re-sequencing and additional exome sequencing.
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Figure 2. Apolipoprotein A-V (APOA5) mutations discovered after sequencing of 13,432 
individuals
Individual mutations (non-synonymous, indel frameshift and splice-site variants with minor 
allele frequency less than 1%) are depicted according to genomic position along the length 
of the APOA5 gene starting at the 5′ end (top). The number of circles on the left and right 
represents the number of times that mutation is observed in cases or controls, respectively. 
Dashed lines across the gene connect the same mutation seen in cases and controls. 
Mutations are shaded in red, blue, or yellow if observed in cases only, controls only, or both 
cases and controls, respectively.
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Figure 3. Low-density lipoprotein receptor (LDLR) mutations discovered after sequencing 9,793 
individuals
A. Individual disruptive mutations (nonsense, indel frameshift, and splice-site variants with 
minor allele frequency less than 1%) are depicted according to genomic position along the 
length of the LDLR gene starting at the 5′ end (top). The number of circles on the left and 
right represents the number of times that mutation is observed in cases or controls, 
respectively. Mutations are shaded in red or blue, if observed in cases only or controls only, 
respectively. B. Low-density lipoprotein cholesterol level as a function of LDLR gene 
mutation annotation. Mean (height of bar) and 95 % confidence intervals (error bars) are 
shown. Each individual is categorized based on mutation annotation as follows. Non-
Carriers: carriers without a missense or disruptive mutation; “Deleterious (PolyPhen)” as 
defined by nonsense, splice-site, indel frameshift, and missense annotated as “possibly 
damaging” or “probably damaging” by PolyPhen-2 HumDiv software; “Deleterious 
(Broad)” as defined by nonsense, splice-site, indel frameshift, and missense annotated as 
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deleterious by at least one of five protein prediction algorithms (LRT score, MutationTaster, 
PolyPhen-2 HumDiv, PolyPhen-2 HumVar and SIFT); “Deleterious (Strict)” as defined by 
nonsense, splice-site, indel frameshift, and missense annotated as deleterious by all five of 
the above protein prediction algorithms; Disruptive: carriers of mutations that are nonsense, 
indel frameshift, or splice-site.
Do et al. Page 25





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nature. Author manuscript; available in PMC 2015 August 05.
